Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Creative Medical Technology Holdings (CELZ) Research & Development (2016 - 2025)

Creative Medical Technology Holdings (CELZ) has disclosed Research & Development for 8 consecutive years, with $550077.0 as the latest value for Q4 2025.

  • Quarterly Research & Development rose 16.58% to $550077.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.3 million through Dec 2025, down 5.87% year-over-year, with the annual reading at $2.3 million for FY2025, 5.87% down from the prior year.
  • Research & Development for Q4 2025 was $550077.0 at Creative Medical Technology Holdings, up from $465154.0 in the prior quarter.
  • The five-year high for Research & Development was $5.4 million in Q4 2022, with the low at $10000.0 in Q1 2022.
  • Average Research & Development over 5 years is $722735.9, with a median of $468497.0 recorded in 2024.
  • The sharpest move saw Research & Development soared 10636.44% in 2022, then crashed 93.49% in 2023.
  • Over 5 years, Research & Development stood at $50000.0 in 2021, then skyrocketed by 10636.44% to $5.4 million in 2022, then plummeted by 93.49% to $349408.0 in 2023, then surged by 35.04% to $471840.0 in 2024, then increased by 16.58% to $550077.0 in 2025.
  • According to Business Quant data, Research & Development over the past three periods came in at $550077.0, $465154.0, and $501261.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.